Erythropoietin in Acute Myocardial Infarction

• Status: Unknown status
• Trial end date: 2008-01-01
• Target enrollment: 0
• Participant gender: All

Summary

Erythropoietin (EPO) is a naturally occuring hormone which regulates the body's response to lack of oxygen and controls the number of red cells in the blood. Recent studies in animals have shown that EPO has protective effects when organs such as the heart and brain are injured by lack of oxygen due to reduced blood supply.

We wish to test the idea that giving a patient, who is having a heart attack, an injection of EPO will reduce the size of the heart attack.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hammersmith Hospitals NHS Trust
• Treatments: Epoetin Alfa

Criteria

Inclusion Criteria:

• Male or female >18 years of age

• Weight between 50 kg and 120 kg

• Suspected of having his/her first-documented STEMI

• Symptoms of ischemia of >20 min with < 6h prior to PCI

• Either 1mm ST elevation in at least two contiguous limb leads or >2mm ST elevation in 2 contiguous chest leads

• Primary PCI to occur within 8h from the onset of symptoms

• Women of childbearing potential must have a negative pregnancy test

Exclusion Criteria:

• Contraindications to MRI scanning

• History or ECG evidence of previous STEMI

• Cardiogenic shock

• NYHA class III-IV heart failure

• LBBB or AF on ECG; 6.Major trauma, major surgery, eye, spinal cord, or brain surgery within the last 3 months

• Significant hepatic disturbance

• Chronic renal impairment (Creatinine >200µmol/L)

• Stroke or TIA <6 months

• Pregnancy or breast-feeding

• Dependence on alcohol or other DOA

• Significant psychiatric/neurologic disease that would prevent adherence to the requirements of the protocol

• Significant immunocompromise (including, but not limited to AIDS and immune-suppressive therapy

• Current treatment with human recombinant erythropoietin

• Current hemodialysis or peritoneal dialysis